Skip to main content

Cabaletta Bio, Inc.

CABA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001759138

No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Cabaletta Bio, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of CABA: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders9386−7
Shares36.3M72.8M+36.5M (+100.4%)
Value$50.3M$110.7M+$60.3M (+119.9%)

New holders (26)

Institutions that held Cabaletta Bio, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to CABA in Q2 2025
InstitutionSharesValue% of portfolio
Cormorant Asset Management, LP5,000,000$7.60M0.57%
Alyeska Investment Group, L.P.4,800,000$7.30M0.03%
Heights Capital Management, Inc3,144,106$4.78M1.50%
Jefferies Financial Group Inc.1,997,208$3.04M0.05%
Burkehill Global Management, LP1,900,000$2.89M0.21%
Anson Funds Management LP1,822,830$2.77M0.51%
Woodline Partners LP1,218,464$1.85M0.01%
Blue Owl Capital Holdings LP1,125,000$1.71M0.55%
Jane Street Group, LLC238,325$362.3K0.00%
Cubist Systematic Strategies, LLC235,270$357.6K0.00%
HRT Financial LP124,395$189.0K0.00%
XTX Topco Ltd97,260$147.8K0.01%
Squarepoint Ops LLC71,441$108.6K0.00%
Jain Global LLC56,160$85.4K0.00%
MYDA Advisors LLC40,000$60.8K0.02%
Point72 Asia (Singapore) Pte. Ltd.34,767$52.8K0.01%
Catalyst Funds Management Pty Ltd21,000$31.9K0.01%
Two Sigma Securities, LLC16,491$25.1K0.00%
Rangeley Capital, LLC16,000$24.3K0.03%
Hudson Bay Capital Management LP13,070$19.9K0.00%
DRW Securities, LLC12,840$19.5K0.00%
Clear Street Markets LLC4,824$7.33K0.00%
Point72 (DIFC) Ltd2,432$3.70K0.00%
Rise Advisors, LLC1,083$1.65K0.00%
Russell Investments Group, Ltd.939$1.43K0.00%
Mid-American Wealth Advisory Group, Inc.91$1380.00%

Sold out (33)

Institutions that held Cabaletta Bio, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.